**MINISTRY OF CHEMICALS AND FERTILISERS**

**DEMAND NO. 7**

Department of Pharmaceuticals

<table>
<thead>
<tr>
<th></th>
<th>Actual 2020-2021</th>
<th>Budget 2021-2022</th>
<th>Revised 2021-2022</th>
<th>Budget 2022-2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revenue</td>
<td>Capital</td>
<td>Total</td>
<td>Revenue</td>
</tr>
<tr>
<td>Gross</td>
<td>449.01</td>
<td>7.15</td>
<td>456.16</td>
<td>461.29</td>
</tr>
<tr>
<td>Recoveries</td>
<td>-0.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receipts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net</td>
<td>448.86</td>
<td>7.15</td>
<td>456.01</td>
<td>461.29</td>
</tr>
</tbody>
</table>

A. The Budget allocations, net of recoveries and receipts, are given below:

**CENTRE’S EXPENDITURE**

Establishment Expenditure of the Centre

1. Secretariat
   - 14.40 (Revenue) [14.40 (Capital)]
   - 16.73 (Total)
   - 15.98 (Revenue) [15.98 (Capital)]
   - 18.56 (Total)

2. National Pharmaceutical Pricing Authority (NPPA)
   - 12.74 (Revenue) [12.74 (Capital)]
   - 14.80 (Total)
   - 14.01 (Revenue) [14.01 (Capital)]
   - 17.79 (Total)

Total Establishment Expenditure of the Centre:

- 27.14 (Revenue) [27.14 (Capital)]
- 31.53 (Total)
- 29.99 (Revenue) [29.99 (Capital)]
- 36.35 (Total)

Central Sector Schemes/Projects

3. National Institutes of Pharmaceutical Education and Research (NIPERs)
   - 306.27 (Revenue) [306.27 (Capital)]
   - 215.34 (Total)
   - 350.00 (Revenue) [350.00 (Capital)]
   - 350.00 (Total)

4. Jan Aushadhi Scheme
   - 65.00 (Revenue) [65.00 (Capital)]
   - 65.00 (Total)
   - 68.50 (Revenue) [68.50 (Capital)]
   - 72.50 (Total)

5. Development of Pharmaceutical Industry
   - 20.45 (Revenue) [20.45 (Capital)]
   - 124.42 (Total)
   - 0.02 (Revenue) [0.02 (Capital)]
   - 0.02 (Total)

6. Consumer Awareness Publicity and Price Monitoring
   - 2.60 (Revenue) [2.60 (Capital)]
   - 6.00 (Total)
   - 4.50 (Revenue) [4.50 (Capital)]
   - 6.00 (Total)

Total Development of Pharmaceutical Industry:

- 17.62 (Revenue) [17.62 (Capital)]
- 100.00 (Total)

Production Linked Incentive Schemes

8. Production Linked Incentive Schemes

8.01 Promotion of Bulk Drug Parks
   - 36.24 (Revenue) [36.24 (Capital)]
   - 36.24 (Total)
   - 900.00 (Revenue) [900.00 (Capital)]
   - 900.00 (Total)

8.02 Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs)/Drug
   - 2.79 (Revenue) [2.79 (Capital)]
   - 2.79 (Total)
   - 390.00 (Revenue) [390.00 (Capital)]
   - 390.00 (Total)
### Notes on Demand for Grants, 2022-2023

#### 8.03 Intermediates (DIIs) and Active Pharmaceutical Ingredients (APIs) in India
- **Promotion of Medical Device Parks**
  - **Actual 2020-2021**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2021-2022**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Revised 2021-2022**: Revenue: \text{137.02}, Capital: \text{137.02}, Total: \text{120.00}
  - **Budget 2022-2023**: Revenue: \text{120.00}, Capital: \text{...}, Total: \text{...}

#### 8.04 Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices
- **Production Linked Incentive Scheme for Pharmaceuticals**
  - **Actual 2020-2021**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2021-2022**: Revenue: \text{3.31}, Capital: \text{3.31}, Total: \text{216.00}
  - **Revised 2021-2022**: Revenue: \text{...}, Capital: \text{3.00}, Total: \text{3.00}
  - **Budget 2022-2023**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}

#### 8.05 Total-Production Linked Incentive Schemes
- **Promotion of Medical Device Parks**
  - **Actual 2020-2021**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2021-2022**: Revenue: \text{182.36}, Capital: \text{182.36}, Total: \text{1629.00}
  - **Revised 2021-2022**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2022-2023**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}

#### Total-Central Sector Schemes/Projects
- **Actual 2020-2021**: Revenue: \text{394.32}, Capital: \text{...}, Total: \text{394.32}
- **Budget 2021-2022**: Revenue: \text{410.76}, Capital: \text{...}, Total: \text{410.76}
- **Revised 2021-2022**: Revenue: \text{623.00}, Capital: \text{...}, Total: \text{623.00}
- **Budget 2022-2023**: Revenue: \text{2157.50}, Capital: \text{...}, Total: \text{2157.50}

### Other Central Sector Expenditure

#### Autonomous Bodies
- **9. National Institute of Pharmaceutical Education and Research (NIPERs)**
  - **Actual 2020-2021**: Revenue: \text{27.55}, Capital: \text{...}, Total: \text{27.55}
  - **Budget 2021-2022**: Revenue: \text{19.00}, Capital: \text{...}, Total: \text{19.00}
  - **Revised 2021-2022**: Revenue: \text{22.00}, Capital: \text{...}, Total: \text{22.00}
  - **Budget 2022-2023**: Revenue: \text{45.00}, Capital: \text{...}, Total: \text{45.00}

#### Public Sector Undertakings
- **10. Assistance to PSUs**
  - **Actual 2020-2021**: Revenue: \text{...}, Capital: \text{7.15}, Total: \text{7.15}
  - **Budget 2021-2022**: Revenue: \text{...}, Capital: \text{9.12}, Total: \text{9.12}
  - **Revised 2021-2022**: Revenue: \text{...}, Capital: \text{148.12}, Total: \text{148.12}
  - **Budget 2022-2023**: Revenue: \text{...}, Capital: \text{5.30}, Total: \text{5.30}

#### 11. Write Off/Waiver of losses in respect of Pharmaceuticals PSUs
- **11.01 India Drugs and Pharmaceuticals Limited (IDPL)**
  - **Actual 2020-2021**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2021-2022**: Revenue: \text{...}, Capital: \text{889.50}, Total: \text{889.50}
  - **Revised 2021-2022**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2022-2023**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}

#### 11.02 Bengal Chemicals & Pharmaceuticals Limited (BCPL)
- **Actual 2020-2021**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2021-2022**: Revenue: \text{...}, Capital: \text{193.71}, Total: \text{193.71}
  - **Revised 2021-2022**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}
  - **Budget 2022-2023**: Revenue: \text{...}, Capital: \text{...}, Total: \text{...}

### Total-Public Sector Undertakings
- **Actual 2020-2021**: Revenue: \text{...}, Capital: \text{7.15}, Total: \text{7.15}
  - **Budget 2021-2022**: Revenue: \text{...}, Capital: \text{9.12}, Total: \text{9.12}
  - **Revised 2021-2022**: Revenue: \text{...}, Capital: \text{148.12}, Total: \text{148.12}
  - **Budget 2022-2023**: Revenue: \text{...}, Capital: \text{5.30}, Total: \text{5.30}

### Total-Other Central Sector Expenditure
- **Actual 2020-2021**: Revenue: \text{27.55}, Capital: \text{7.15}, Total: \text{34.70}
  - **Budget 2021-2022**: Revenue: \text{19.00}, Capital: \text{9.12}, Total: \text{28.12}
  - **Revised 2021-2022**: Revenue: \text{22.00}, Capital: \text{148.12}, Total: \text{170.12}
  - **Budget 2022-2023**: Revenue: \text{45.00}, Capital: \text{5.30}, Total: \text{50.30}

## TRANSFERS TO STATES/UTs

### Other Grants/Loans/Transfers
- **12. Recovery**
  - **Actual 2020-2021**: Revenue: \text{-0.15}, Capital: \text{...}, Total: \text{-0.15}

### Grand Total
- **Actual 2020-2021**: Revenue: \text{448.86}, Capital: \text{7.15}, Total: \text{456.01}
  - **Budget 2021-2022**: Revenue: \text{461.29}, Capital: \text{9.12}, Total: \text{470.41}
  - **Revised 2021-2022**: Revenue: \text{674.99}, Capital: \text{148.12}, Total: \text{823.11}
  - **Budget 2022-2023**: Revenue: \text{2238.85}, Capital: \text{5.30}, Total: \text{2244.15}

### B. Developmental Heads

#### Economic Services
- **1. Industries**
  - **Actual 2020-2021**: Revenue: \text{434.46}, Capital: \text{...}, Total: \text{434.46}
  - **Budget 2021-2022**: Revenue: \text{406.85}, Capital: \text{...}, Total: \text{406.85}
  - **Revised 2021-2022**: Revenue: \text{596.70}, Capital: \text{...}, Total: \text{596.70}
  - **Budget 2022-2023**: Revenue: \text{2178.09}, Capital: \text{...}, Total: \text{2178.09}

---

No. 7/Department of Pharmaceuticals

*(In ₹ crores)*
Notes on Demands for Grants, 2022-2023

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Revenue</td>
<td>Capital</td>
<td>Total</td>
<td>Revenue</td>
</tr>
<tr>
<td></td>
<td>14.40</td>
<td>...</td>
<td>14.40</td>
<td>16.73</td>
</tr>
<tr>
<td>3. Loans for Chemical and Pharmaceutical Industries</td>
<td>...</td>
<td>7.15</td>
<td>7.15</td>
<td>...</td>
</tr>
<tr>
<td>Total-Economic Services</td>
<td>448.86</td>
<td>7.15</td>
<td>456.01</td>
<td>423.58</td>
</tr>
<tr>
<td>Others</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>4. North Eastern Areas</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>37.71</td>
</tr>
<tr>
<td>Total-others</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>37.71</td>
</tr>
<tr>
<td>Grand Total</td>
<td>448.86</td>
<td>7.15</td>
<td>456.01</td>
<td>461.29</td>
</tr>
</tbody>
</table>

C. Investment in Public Enterprises

1. Karnataka Antibiotics and Pharmaceuticals Ltd | ... | 23.18 | 23.18 | ... | 33.75 | 33.75 | ... | 30.00 | 30.00 | ... | 33.00 | 33.00 |
2. Indian Drugs and Pharmaceuticals Ltd | 2.23 | ... | 2.23  | ... | ... | ...  | 2.00 | ... | 2.00  | 4.00 | ... | 4.00  |
3. Hindustan Antibiotics Ltd | 2.52 | ... | 2.52  | ... | ... | ...  | 122.09 | ... | 122.09 | 1.26 | ... | 1.26  |
4. Bengal Chemicals and Pharmaceuticals Ltd | ... | ... | ...  | ... | ... | ...  | 0.01 | ... | 0.01  | 0.01 | ... | 0.01  |
5. Bengal Immunity Ltd | ... | ... | ...  | ... | ... | ...  | 0.01 | ... | 0.01  | 0.01 | ... | 0.01  |
6. Rajasthan Drugs and Pharmaceuticals Ltd | 2.40 | ... | 2.40  | ... | ... | ...  | 24.00 | ... | 24.00 | 0.01 | ... | 0.01  |
7. Smith Stanistreet Pharmaceuticals Ltd | ... | ... | ...  | ... | ... | ...  | 0.01 | ... | 0.01  | 0.01 | ... | 0.01  |
| Total | 7.15 | 23.18 | 30.33 | ... | 33.75 | 33.75 | 148.12 | 30.00 | 178.12 | 5.30 | 33.00 | 38.30 |

1. **Secretariat:** The provision is for the Salary and Establishment Expenditure of Department of Pharmaceuticals.

2. **National Pharmaceutical Pricing Authority (NPPA):** The provision is for the Secretariat and Establishment Expenditure of NPPA.

3. **National Institutes of Pharmaceutical Education and Research (NIPERs):** The provision is made for 7 NIPERs i.e. Mohali, Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata and Rae Bareli for incurring establishment and other expenditure.

4. **Jan Aushadhi Scheme:** Under the Jan Aushadhi Scheme for effective implementation of Pradhan Mantri Bhartiya Janaushadhi Pariyojana(PMBJP).

5. **Consumer Awareness Publicity and Price Monitoring:** The provision is for Consumer Awareness, Publicity and providing support to State resource units.

6. **Pharmaceutical Promotion & Development Scheme(PPDS):** The provision for promotion, development and export promotion in Pharmaceuticals sector by extending financial support for conduct of seminars, conferences, exhibitions, mounting delegation to and from India for promotion of exports as well as investments, conduct studies/consultancies for facilitating growth, export as well as critical issues affecting Pharma Sector.

7. **Assistance to Pharmaceutical Industry for Common Facilities(API-CF)/Cluster Development:** The Scheme would be implemented in a Public Private Partnership (PPP) mode through one time grant-in-aid to be released in various phases for creation of identified infrastructure and common facilities to a Special Purpose Vehicles (SPVs) set up for the purpose.

---

No. 7/Department of Pharmaceuticals
7.03. **Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS):** The sub-scheme is aimed at providing interest subvention to the eligible Small and Medium Scale Pharma Units having GMP compliant manufacturing facilities both for Bulk Drugs and Pharmaceuticals formulations. The eligible units intending to upgrade their manufacturing infrastructure to attain WHO-GMP norms, have to secure loan from any Financial Institution for upgrading their infrastructure and technology.

8.01. **Promotion of Bulk Drug Parks:** To promote setting up of bulk drug parks in the country for providing easy access to world class Common Infrastructure Facilities (CIF) to bulk drug units located in the park in order to significantly bring down the manufacturing cost of bulk drugs and thereby make India self-reliant in bulk drugs by increasing the competitiveness of the domestic bulk drug industry.

8.02. **Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India:** The objective of the scheme is to attain self-reliance and reduce import dependence in critical KSMs/DIs/APIs. Under the scheme, financial incentives shall be given based on committed investment and sales made by selected applicant for the eligible products.

8.03. **Promotion of Medical Device Parks:** Creation of world class infrastructure facilities in order to make Indian medical device industry a global leader. Easy access to standard testing and infrastructure facilities through creation of world class Common Infrastructure Facilities for increased competitiveness will result in significant reduction of the cost of production of medical devices leading to better availability and affordability of medical devices in the domestic market.

8.04. **Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices:** The scheme proposes a financial incentive to boost domestic manufacturing and attract large investment in the Medical Device Sector.

8.05. **Production Linked Incentive Scheme for Pharmaceuticals:** The objective of the scheme is to enhance India manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector.

9. **National Institute of Pharmaceutical Education and Research (NIPERs):** The provision has been made for salary of employees of 7 NIPERs i.e. Mohali, Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata and Rae Bareli.

10. **Assistance to PSUs:** These are provisions under loan kept for the 6 Pharmaceuticals Public Sector Undertakings (PSUs).